Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia
- PMID: 37532412
- DOI: 10.1016/S2352-3026(23)00213-2
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia
Conflict of interest statement
MY reports receiving research grants from Daiichi Sankyo and Pfizer; and consulting fees from Daiichi Sankyo, Pfizer, and Cardinal Health. ND reports receiving research grants or contracts from Daiichi Sankyo, Bristol Meyers Squibb, Pfizer, Gilead Sciences, Servier, Genentech, Astellas Pharma, AbbVie, ImmunoGen, Amgen, Trillium Therapeutics, Hanmi Pharmaceutical, Trovagene, Fate Therapeutics, Novimmune, GlycoMimetics, and Kite Pharma; and consulting fees from Daichii Sankyo, Bristol Meyers Squibb, Pfizer, Gilead Sciences, Servier, Genentech, Astellas Pharma, AbbVie, ImmunoGen, Amgen, Trillium Therapeutics, Arog Pharmaceuticals, Novartis, Jazz Pharmaceuticals, Celgene, Syndax, Shattuck Labs, Agios, Kite Pharma, and Stemline/Menarini.
Comment on
-
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.Lancet Haematol. 2023 Aug;10(8):e600-e611. doi: 10.1016/S2352-3026(23)00117-5. Epub 2023 Jul 3. Lancet Haematol. 2023. PMID: 37414062 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
